WALTHAM, Mass.--(BUSINESS WIRE)--Repligen Corporation (NASDAQ: RGEN) announced today that Robert A. Spurr has joined the Company as Senior Vice President of Sales and Marketing and Chief Commercial Officer. Mr. Spurr brings to Repligen more than 25 years of commercial experience in the sales and marketing of imaging and pharmaceutical products. In this new role, Mr. Spurr will be responsible for all commercial activities for the Company including establishing the commercial organization to sell SecreFlo™ in the U.S. pending approval by the FDA and overseeing the commercial operations of our bioprocessing business including expanding the sales of our recently launched Opus™ product line to biopharmaceutical customers.
